I recently completed the Ph.D program in Pharmacology and Toxicology and currently work as a Postdoctoral Fellow doing laboratory research on regulation of xenobiotic transporters at Kansas University Medical Center

My dissertation focused on environmental arsenic exposure is associated with human cancers of the skin, lung, kidney, and bladder. Mechanisms of arsenic toxicity and carcinogenicity, however, remain poorly studied and merit further investigation. My dissertation studies addressed the effects of arsenic metabolism on toxicity, under the hypothesis that arsenic metabolism results in both detoxication and bioactivation. Inorganic arsenic and methylated metabolites were tested for toxicity in cultured cells, demonstrating that both detoxification and bioactivation occur with metabolism, dependent upon methylation and valence state. Monomethylated MMAIII, the most toxic metabolite in cultured cells was also a potent inhibitor of pyruvate dehydrogenase and was more lethal than arsenite in hamsters, illustrating its role as an arsenic bioactivation product. Additionally, the lung is an established target of arsenic exposure. Arsenic also crosses placenta during pregnancy, reaching the developing fetus. Given this evidence, my dissertation project investigated the ability of arsenic to target the developing lung following in utero exposure to low doses of arsenic during fetal development. Fetal rats were exposed to 500 _g/L arsenic via maternal drinking water, from conception to embryonic day eighteen.

In order to assess toxicogenetic alterations in the developing lung, subtractive hybridization was used to create a cDNA library of arsenic-induced differential gene expression. This library consisted of 326 clones that were subsequently spotted on a cDNA microarray, including those involved in lung development and in formation of the extracellular matrix. In order to model effects of arsenic on gene expression in the developing lung, microarrays were conducted utilizing cultured lung cells dosed with four sub-cytotoxic doses of arsenic for up to fourteen days. These arrays showed that arsenic modulates a decreasing number of genes over the time course and that genes are primarily upregulated following short exposures. Selected array and subtracted library gene expression was also evaluated by quantitative real time PCR and western immunoblotting. Additional microarrays were conducted with 500 ppb arsenic treated fetal lung tissue using a commercial cDNA microarray, revealing perturbations in cellular proliferation and angiogenesis genes in vivo. Collectively, these studies indicate that lung development can be perturbed by gestational arsenic exposure.